Views & Analysis The PPRS medicines pricing scheme: is it working for both si... The PPRS has now reached the half-way stage - a look at the stats so far.
Views & Analysis Flexible models for better access Which initiatives are the most likely to bring life-changing therapies to patients?
Views & Analysis Sitting uncomfortably? The UK’s PPRS and statutory schemes Do the PPRS and the statutory scheme run effectively in parallel?
Views & Analysis Access to cancer drugs: planning for every outcome New UK oncology drug assessment procedures examined.
Views & Analysis Patient Access Schemes: a look behind the scenes Leela Barham takes a look behind the schemes for patient access in England and puts the case for a review to bring them up to date, in the light of changes since they began in 2009.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
